Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Associated Therapies: -

Clinical Trials

Prasugrel Versus Placebo in Adult Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Anemia

Interventions: Drug: Prasugrel
Drug: Placebo

First Posted Date: 2010-07-21

Last Posted Date: 2012-05-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 62

Registration Number: NCT01167023

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis

Phase 3

Completed

Conditions: Chronic Renal Failure
Hemodialysis

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2010-07-02

Last Posted Date: 2010-11-16

Lead Sponsor: University of Patras

Target Recruit Count: 70

Registration Number: NCT01155765

Locations: 🇬🇷
Patras University Hospital, Patras, Achaia, Greece

Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Placebo
Drug: Clopidogrel

First Posted Date: 2010-05-04

Last Posted Date: 2012-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 282

Registration Number: NCT01115738

Locations: 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).

Phase 3

Completed

Conditions: Coronary Artery Disease (CAD)
Acute Coronary Syndrome (ACS)

Interventions: Drug: prasugrel
Drug: clopidogrel

First Posted Date: 2010-04-23

Last Posted Date: 2010-08-24

Lead Sponsor: University of Patras

Target Recruit Count: 70

Registration Number: NCT01109784

Locations: 🇬🇷
Cardiology Department, Patras University Hospital, Rio, Patras, Greece

Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: clopidogrel
Drug: prasugrel

First Posted Date: 2010-04-21

Last Posted Date: 2012-10-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 155

Registration Number: NCT01107912

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden

Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: prasugrel
Drug: clopidogrel

First Posted Date: 2010-04-21

Last Posted Date: 2012-08-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT01107925

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden

Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes

Phase 1

Terminated

Conditions: Acute Coronary Syndromes

Interventions: Drug: clopidogrel
Drug: prasugrel

First Posted Date: 2010-04-21

Last Posted Date: 2012-03-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT01107899

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany

The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation

Phase 4

Completed

Conditions: Healthy Volunteers
Sepsis

Interventions: Drug: Placebo
Drug: Prasugrel

First Posted Date: 2010-04-07

Last Posted Date: 2011-07-11

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 20

Registration Number: NCT01099566

Locations: 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction

Phase 3

Completed

Conditions: Acute Coronary Syndromes

Interventions: Drug: Placebo
Drug: Prasugrel

First Posted Date: 2009-11-18

Last Posted Date: 2014-02-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 4033

Registration Number: NCT01015287

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sisli, Turkey

Prasugrel/Clopidogrel Maintenance Dose Washout Study

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2009-11-17

Last Posted Date: 2021-06-28

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 56

Registration Number: NCT01014624

Locations: 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸
Black Hills Clinical Research Center, Rapid City, South Dakota, United States
🇺🇸
University of Florida Health Science Center Shands Jacksonville, Jacksonville, Florida, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy